Drug intelligence / Profile preview

VR2081

Development stage: Preclinical
Lead developer: Phillips-Medisize
Modality: Small Molecules
Administration: Inhalation

Overview

VR2081 is a Vectura-developed, Sandoz-licensed US generic pressurized metered-dose inhaler program for an undisclosed existing inhaled combination therapy used in asthma and chronic obstructive pulmonary disease. Vectura was responsible for formulation development and manufacture of clinical trial batches, while Sandoz was responsible for clinical development, commercial manufacturing, and commercialization. Publicly available program disclosures do not identify the reference product, active ingredients, or specific molecular targets.

Beyond the preview

Go deeper on VR2081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VR2081.

Explore the full profile